Cargando…
Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
The oligometastatic state is hypothesized to represent an intermediary state of cancer between widely metastatic disease and curable, localized disease. Advancements in radiotherapy have allowed for delivery of high precision, dose escalated treatment known as stereotactic body radiotherapy (SBRT) t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504814/ https://www.ncbi.nlm.nih.gov/pubmed/31119099 http://dx.doi.org/10.3389/fonc.2019.00337 |
_version_ | 1783416639218253824 |
---|---|
author | Zeng, Kang Liang Tseng, Chia-Lin Soliman, Hany Weiss, Yonatan Sahgal, Arjun Myrehaug, Sten |
author_facet | Zeng, Kang Liang Tseng, Chia-Lin Soliman, Hany Weiss, Yonatan Sahgal, Arjun Myrehaug, Sten |
author_sort | Zeng, Kang Liang |
collection | PubMed |
description | The oligometastatic state is hypothesized to represent an intermediary state of cancer between widely metastatic disease and curable, localized disease. Advancements in radiotherapy have allowed for delivery of high precision, dose escalated treatment known as stereotactic body radiotherapy (SBRT) to targets throughout the body with excellent rates of local control. Recently, the first phase II randomized trial comparing conventional radiotherapy to comprehensive SBRT of oligometastatic disease demonstrated an overall survival and progression free survival advantage. The spine is a common site of metastasis, and a complex site for SBRT given the adjacent spinal cord and the tumor embedded within the bone tissue putting the patient at risk of fracture. Although there are expert spine SBRT guidelines for practice, there are as yet no reported randomized trials that proves superiority as compared to conventional radiation. The use of SBRT in patients with oligometastatic disease and spinal metastases is the focus of this review. |
format | Online Article Text |
id | pubmed-6504814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65048142019-05-22 Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview Zeng, Kang Liang Tseng, Chia-Lin Soliman, Hany Weiss, Yonatan Sahgal, Arjun Myrehaug, Sten Front Oncol Oncology The oligometastatic state is hypothesized to represent an intermediary state of cancer between widely metastatic disease and curable, localized disease. Advancements in radiotherapy have allowed for delivery of high precision, dose escalated treatment known as stereotactic body radiotherapy (SBRT) to targets throughout the body with excellent rates of local control. Recently, the first phase II randomized trial comparing conventional radiotherapy to comprehensive SBRT of oligometastatic disease demonstrated an overall survival and progression free survival advantage. The spine is a common site of metastasis, and a complex site for SBRT given the adjacent spinal cord and the tumor embedded within the bone tissue putting the patient at risk of fracture. Although there are expert spine SBRT guidelines for practice, there are as yet no reported randomized trials that proves superiority as compared to conventional radiation. The use of SBRT in patients with oligometastatic disease and spinal metastases is the focus of this review. Frontiers Media S.A. 2019-05-01 /pmc/articles/PMC6504814/ /pubmed/31119099 http://dx.doi.org/10.3389/fonc.2019.00337 Text en Copyright © 2019 Zeng, Tseng, Soliman, Weiss, Sahgal and Myrehaug. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zeng, Kang Liang Tseng, Chia-Lin Soliman, Hany Weiss, Yonatan Sahgal, Arjun Myrehaug, Sten Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview |
title | Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview |
title_full | Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview |
title_fullStr | Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview |
title_full_unstemmed | Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview |
title_short | Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview |
title_sort | stereotactic body radiotherapy (sbrt) for oligometastatic spine metastases: an overview |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504814/ https://www.ncbi.nlm.nih.gov/pubmed/31119099 http://dx.doi.org/10.3389/fonc.2019.00337 |
work_keys_str_mv | AT zengkangliang stereotacticbodyradiotherapysbrtforoligometastaticspinemetastasesanoverview AT tsengchialin stereotacticbodyradiotherapysbrtforoligometastaticspinemetastasesanoverview AT solimanhany stereotacticbodyradiotherapysbrtforoligometastaticspinemetastasesanoverview AT weissyonatan stereotacticbodyradiotherapysbrtforoligometastaticspinemetastasesanoverview AT sahgalarjun stereotacticbodyradiotherapysbrtforoligometastaticspinemetastasesanoverview AT myrehaugsten stereotacticbodyradiotherapysbrtforoligometastaticspinemetastasesanoverview |